Ascentage Pharma Group Internat

Ascentage Pharma Group International is a clinical-stage biotechnology company based in China that focuses on developing therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases. Its lead product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants including the T315I mutation. The company also has a robust pipeline including APG-2575, an oral Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral MDM2-p53 inhibitor for solid tumors and hematological malignancies; APG-1252, a dual Bcl-2/Bcl-xL inhibitor for small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumors, and non-Hodgkin's lymphoma; APG-1387, a small-molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV; and APG-5918, an orally available selective embryonic ectoderm development inhibitor. The company also engages in medical R&D, clinical trials operations, venture capital investment, and rental of buildings.

Ascentage Pharma Group International is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol AAPG. Its shares trade in US Dollars (USD). The company is headquartered in Suzhou, China, and its primary operations are in Mainland China, but it is listed on a US exchange, providing international investors access to its stock.

Ascentage Pharma Group International operates in the Healthcare sector, specifically within the Biotechnology industry. As a clinical-stage biotechnology company, it focuses on developing innovative therapies for serious diseases such as cancers, chronic hepatitis B virus (HBV), and age-related conditions. The company's work involves cutting-edge research in targeted therapies, including inhibitors for BCR-ABL, Bcl-2, MDM2-p53, and apoptosis proteins, positioning it within the biotech field dedicated to precision medicine and oncology.

Ascentage Pharma Group International is headquartered in Suzhou, China, and its primary market is Mainland China. The company was founded in 2009 and focuses on developing therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases. While its operations are centered in China, it collaborates with biotechnology and pharmaceutical companies as well as research institutions globally. Its listing on the NasdaqGM exchange also indicates a presence in the US capital markets, though its core research and development activities are conducted in China.

Ascentage Pharma Group International is a clinical-stage biotechnology company, meaning it has not yet commercialized any products and currently generates revenue primarily through medical research and development activities, venture capital investments, rental of buildings, and provision of science and technology promotion services. The company's main focus is on advancing its pipeline of drug candidates through clinical trials. It has collaboration relationships with other biotechnology and pharmaceutical companies and research institutions, which may provide funding or partnership opportunities. Once its product candidates receive regulatory approval, the company expects to generate revenue from sales of those therapies, but as of now, it remains in the development phase.